Lung Cancer Center, Chicago

Your treatment options

Lung Cancer Center

The Lung Cancer Center at Cancer Treatment Centers of America® (CTCA), Chicago, is designed to bring together a wide array of medical professionals devoted to diagnosing patients who have had test results that suggested they may have lung cancer, while also treating and assisting patients who have already been diagnosed with the disease. Our team of cancer experts is committed to helping you make informed decisions about the options available to treat your disease and manage the side effects that may result.

Having a team of lung cancer experts collaborating daily, all under one roof, allows us to design a detailed treatment plan tailored to your tumor type, stage, genomic markers and other needs more quickly and efficiently. In this era of precision and personalized medicine, and based on your specific needs, our lung experts look to incorporate new and emerging treatments and technologies—including genomic-based cancer care, immunotherapy and targeted drug therapy—into every aspect of your treatment plan.

Learn more about lung cancer treatment options at CTCA®.

U.S. News & World Report names CTCA Chicago high-performing hospital for lung cancer surgery

Each year, U.S. New & World Report evaluates the performance of nearly 4,400 hospitals nationwide in lung cancer surgery using data on patient survival, nurse staffing, volume and more. Hospitals receive one of three ratings: high-performing, average or below-average.

For 2019-20 and again for 2020-21, CTCA Chicago received the highest possible ranking for lung cancer surgery, named a “high-performing” hospital in this category.

US News High Performance  Lung

Meet our Lung Cancer Center doctors

Our oncologists, surgeons, interventional pulmonologists and supportive care clinicians are committed to helping you understand the complexities of your disease and the array of treatment options available to you, so you can make informed decisions about your care. The experts at the CTCA® Lung Cancer Center in Chicago have combined expertise in delivering standard-of-care and advanced techniques for treating lung cancer. The Lung Cancer Center is led by board-certified Medical Oncologist Bruce Gershenhorn, DO, who completed a fellowship at Montefiore Medical Center in Bronx, New York, where he served as Chief Fellow in the Department of Hematology/Oncology. Read more about Dr. Gershenhorn, and each of the other Lung Cancer Center doctors, by exploring the links below.

Peter Baik

Thoracic Surgeon

Ryan Engel

Ryan Engel

Medical Oncologist


Jalal S. Baig

Medical Oncologist

Evan Pisick - Medical Oncologist

Evan Pisick

Genitourinary Medical Oncology Clinical Advisor, Chief of Medical Oncology, CTCA Chicago

Karen Smorowski - Radiation Oncologist

Karen Smorowski

Radiation Oncologist, CTCA Chicago

Karan Shah

Radiation Oncologist, CTCA Chicago

Yiping Fu - Interventional Pulmonologist

Yiping Fu

Interventional Pulmonologist, CTCA Chicago


Kumar Gaurav

Interventional Pulmonologist & Critical Care Physician

Get lung cancer facts

A comprehensive team approach

The clinical team working with our patients in the Lung Cancer Center are part of a wider team of multidisciplinary cancer experts who work together, collaborating daily with the patient and one another, all under one roof. Theirs is a synergy that comes from combining years of expertise and varied skills toward a single cause—treating lung cancer patients.

Each patient’s Lung Cancer Center care team is led by a medical oncologist and coordinated by a care manager, who is devoted to the many details needed to help patients achieve their treatment goals and maintain their quality of life. Our lung cancer pathologists also play a key role in diagnosing and staging the disease, to better pinpoint the treatment options available.

Various other doctors and clinicians may be assigned to your care team to help you meet your treatment goals and manage lung cancer-related side effects. For example, depending on your lung cancer type, stage and recommended treatment plan, your care team may include radiation oncologists, interventional pulmonologists, oncology nurses and a host of supportive care clinicians, all joining together to design a personalized care plan with a commitment to comprehensive care.


Cecil L.

Lung Cancer

"Just walking into the center, I got such a positive first impression. I got a sense of hope as soon as I walked through the doors. I felt nervous excitement radiate through me. And later on, when I talked to other patients, they experienced the same feeling and sensation. Everybody's friendly, they greet you warmly, and you just feel secure. I felt like I was in the right place for me. I just had this feeling that good things were going to happen.


More About CECIL

Our four-day lung nodule diagnosis program

Lung cancer is the second most common non-skin cancer among American men and women, after prostate cancer in men and breast cancer in women. Patients have more treatment options when the disease is diagnosed in its early stages than when it has advanced to later stages. We know the stress and uncertainty that comes with news that an X-ray or CT scan has revealed an abnormal spot on your lung. One of the first things you’ll need to know is if the suspicious mass or nodule is cancerous or benign. Getting a fast, accurate diagnosis is essential to your peace of mind, and your future care, no matter the result. The Lung Cancer Center team of cancer experts understands that time is of the essence and works quickly to provide a diagnosis—in as few as four days—and, if necessary, a treatment plan that meets your needs. Our lung cancer experts have designed a four-day diagnostic program, because they want their patients to get the comprehensive care they need more quickly.

Learn more about our four-day lung nodule diagnosis program.

Lung cancer clinical trials

Our Lung Cancer Center in Chicago is dedicated to offering innovative, leading-edge treatment options. One way to do that is by offering carefully selected lung cancer clinical trials in areas like immunotherapy, interventional pulmonology and chemotherapy. Clinical trials are an essential testing ground for measuring the effectiveness of drugs and other treatments before they can win FDA approval. Trials may offer participants new options that would otherwise be unavailable to them. See our Clinical Trials Q&A to learn more. Find out about the various lung cancer trials underway at CTCA.

Clinical trials Q&A

Are they only available to patients who have exhausted other lung cancer treatment options?

Lung cancer patients may qualify to participate in a clinical trial at any stage of their treatment journey. Some patients may join a clinical trial when they first start treatment, in conjunction with standard therapy, on the chance it may offer improved outcomes. Other trials are designed for lung cancer patients who have not responded adequately to conventional treatments. Your Lung Cancer Center oncologist will discuss the options and risks, and explain the various protocols involved.

How does CTCA select the trials it offers?

At CTCA, our Lung Cancer Center experts never stop searching for innovative ways to treat lung cancer. Offering carefully selected clinical trials helps us fulfill that mission. The new generation of precision drugs is generally designed to deliver more targeted, less toxic therapies. Our Lung Cancer Center oncologists decide to participate as a clinical trial site only after careful consideration of the relative benefit to patients.

Who may benefit from lung cancer clinical trials?

The answer is based on a case-by-case analysis of each lung cancer patient. This is a time of rapid scientific advances in lung cancer treatment. New surgical techniques are being developed with a goal of attacking lung tumors while reducing the amount of trauma to healthy tissue. Meanwhile, a new generation of lung cancer therapies is designed to attack tumors that have specific genomic mutations. These new targeted treatments may be more effective and cause fewer side effects than traditional chemotherapy. But they are so specialized that only a limited subset of lung cancer patients qualifies for participation. The immunotherapy drug nivolumab, for example, is approved for patients with non-squamous non-small cell lung cancer who have already tried platinum-based chemotherapy or EGFR- or ALK-targeted agents. Genomic tumor testing may determine whether you are a candidate. Other factors—such as your cancer mutations and stage, how you have responded to past treatments and other individual considerations—may also determine whether you qualify for specific trials.

How do I find out whether a specific clinical trial may benefit me?

Your Lung Cancer Center oncologist and care team may recommend a trial depending on your individual needs and treatment goals. Learn more about ongoing clinical trials at CTCA. For general questions, contact an Oncology Information Specialist at 888-841-9129.

Learn more about lung cancer clinical trials being offered at CTCA.

Where we are located

CTCA Chicago

Lung Cancer Center
2520 Elisha Ave.
Zion, IL 60099

New Patients:888-552-6760
Existing Patients:(847) 510-CTCA

Get directions

New research

Offering clinical trials on new and emerging cancer treatment options.

View our clinical trials

What’s your risk?

Assess your cancer risk and take control

Assess your cancer risk

Insurance plans

We accept a wide range of insurance plans.

Verify your insurance